Correction to: The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis
An amendment to this paper has been published and can be accessed via the original article.
Main Authors: | Monchanok Vijarnsorn, Irin Kwananocha, Narudee Kashemsant, Thitichai Jarudecha, Chalermpol Lekcharoensuk, Brian Beale, Bruno Peirone, B. Duncan X. Lascelles |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | BMC Veterinary Research |
Online Access: | https://doi.org/10.1186/s12917-020-02713-9 |
Similar Items
-
In Vitro Anti-Inflammatory and Regenerative Effects of Autologous Conditioned Serum from Dogs with Osteoarthritis
by: Sirikul Soontararak, et al.
Published: (2022-10-01) -
Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: A prospective, block-randomized, double-blinded, placebo-controlled clinical trial
by: Naruepon Kampa, et al.
Published: (2023-02-01) -
Corrigendum: Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: a prospective, block-randomized, double-blinded, placebo-controlled clinical trial
by: Naruepon Kampa, et al.
Published: (2023-08-01) -
Use of firocoxib for the treatment of equine osteoarthritis
by: Donnell JR, et al.
Published: (2014-11-01) -
Testing the Neuroprotective Properties of PCSO-524<sup>®</sup> Using a Neuronal Cell Cycle Suppression Assay
by: Beika Zhu, et al.
Published: (2019-01-01)